SARS-CoV2 Clinical Trial
— RUXO-COVIDOfficial title:
Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection
Verified date | April 2021 |
Source | University of Sao Paulo General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The COVID-19 pandemic has had a dramatic effect in public health worldwide. In Brazil, there have been more than 2 million confirmed cases and over 75,000 deaths since February 26, 2020. Based on reports of a hyperinflammatory state associated with COVID-19, the use of immunosuppressive drugs may be efficacious in the treatment of this disease. JAK inhibitors have been shown to harness inflammation in a number of different pathologic conditions. The aim of the present study is to evaluate the efficacy and safety of JAK inhibitor ruxolitinib in patients with acute respiratory distress syndrome due to COVID-19.
Status | Terminated |
Enrollment | 5 |
Est. completion date | March 29, 2021 |
Est. primary completion date | March 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 95 Years |
Eligibility | Inclusion Criteria: - Patients hospitalized with SARS-CoV-2 pneumonia confirmed by RT-PCR or serology (IgA); - PaO2/FiO2 < 300 (not fully explained by heart failure or volume overload) or SpO2 < 90% on room air. Exclusion Criteria: - Symptom onset > 14 days; - Neutrophil count < 1,000/mm3; - Platelets < 50,000/mm3; - ICU care at enrollment; - On invasive mechanical ventilation at enrollment; - Current use of experimental therapy for COVID-19 (except: azithromycin or corticosteroids) - Uncontrolled arterial hypertension; - Current or previous use of systemic immunosuppressive therapy in the last 30 days; - Pregnancy or lactation; - Estimated creatinine clearance < 30 mL/min or receiving CRRT or intermittent hemodialysis; - Allergy to ruxolitinib; - Active tuberculosis; - HIV seropositivity; - Prior history of progressive multifocal leukoencephalopathy; - Use of any JAK inhibitor in the last 30 days before study enrollment; - Not qualifying according to investigators' perception. |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital das Clínicas | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
Vanderson Geraldo Rocha |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | A composite outcome of death or ICU admission or mechanical ventilation at day 14. | 14 days | ||
Secondary | A composite outcome of death or ICU admission or mechanical ventilation at day 28 | 28 days | ||
Secondary | Time to treatment failure | ICU admission, mechanical ventilation, death or consent withdrawal | 28 days | |
Secondary | Overall survival at days 14 and 28 | 14 and 28 days | ||
Secondary | Cumulative incidence of ICU admission rate at days 14 and 28 | 14 and 28 days | ||
Secondary | Cumulative incidence of mechanical ventilation at days 14 and 28 | 14 and 28 days | ||
Secondary | Duration of hospital stay | 28 days | ||
Secondary | Duration of ICU stay | 28 days | ||
Secondary | Duration of mechanical ventilation | 28 days | ||
Secondary | Duration of non-invasive ventilation | 28 days | ||
Secondary | Secondary hemophagocytic syndrome rate | 28 days | ||
Secondary | Cumulative incidence nosocomial infection rate at days 14 and 28 | 14 and 28 days | ||
Secondary | Incidence of discontinuation of oxygen supplementation at days 14 and 28 | 14 and 28 days | ||
Secondary | Rate of grade 1-2 and 3-5 emerging adverse events at day 28 | 28 days | ||
Secondary | Cumulative dose of methylprednisolone at days 14 and 28 | 14 and 28 days | ||
Secondary | Change in PaO2/FiO2 ratio from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in interleukin 6 levels [pg/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in d-dimer levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in fibrinogen levels [mg/dL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in ferritin levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in C reactive protein levels [mg/L] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in alanine aminotransferase [U/L] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in aspartate aminotransferase [U/L] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in creatinine levels [mg/dL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in glucose levels [mg/dL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in hemoglobin levels [g/dL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in platelet count [x10ˆ3/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in absolute neutrophil count [x10ˆ3/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in absolute neutrophil count [/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in absolute lymphocyte count [/mmˆ3] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in prothrombin time ratio from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in partial thromboplastin time ratio from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in bilirubin [mg/dl] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in lactate dehydrogenase [U/L] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in CPK-MB [ng/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in troponin [ng/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in von Willebrand factor antigen level (VWF:Ag) [%] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in von Willebrand factor activity (ristocetin cofactor) [%] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in ADAMTS-13 [%] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in von Willebrand multimeters from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in plasminogen activator inhibitor-1 levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in E-selectin levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in P-selectin levels [ng/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in endothelin [fmol/mL] from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in circulating microparticles from baseline to days 14 and 28 | 14 and 28 days | ||
Secondary | Change in thromboelastography from baseline to days 14 and 28 | 14 and 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04446065 -
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
|
Phase 2/Phase 3 | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Completed |
NCT04463004 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
Recruiting |
NCT04441372 -
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
|
||
Recruiting |
NCT04581148 -
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
|
||
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Completed |
NCT04530604 -
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
|
Phase 1 | |
Active, not recruiting |
NCT04635605 -
Methylene Blue Treatment of COVID-19
|
Phase 2 | |
Recruiting |
NCT04395599 -
Risk of Air Contamination During Visceral Surgery in COVID19 Patients
|
N/A | |
Recruiting |
NCT04472585 -
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04411433 -
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
|
Phase 3 | |
Completed |
NCT04359706 -
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
|
||
Recruiting |
NCT04395794 -
SARS-CoV-2 Disguise Study
|
||
Completed |
NCT04386551 -
Detection of COVID-19 in Saliva Collection
|
||
Recruiting |
NCT04403269 -
NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE
|
Phase 2 | |
Withdrawn |
NCT04379492 -
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
|
Phase 2 | |
Completed |
NCT04379336 -
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
|
Phase 3 |